Polymorphism of PfATPase in Niger: Detection of Three New Point Mutations

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2009 Feb 20

PMID 19226462

Citations 22

Authors

Maman Laminou Ibrahim

Nimol Khim

Hassane Hadiza Adam

Frederic Ariey

Jean-Bernard Duchemin

Affiliations

Soon will be listed here.

Abstract

Background: Plasmodium falciparum resistance to drugs remains a major public health issue in Niger. The therapeutic failure index for chloroquine and sulphadoxine-pyrimethamine are, respectively 20% and 21.9%. In December 2005, the National Malaria Control Programme promoted the use of artemisinin combination therapy (ACT) as first-line treatment of the uncomplicated malaria cases. Recently, studies have shown a relationship between the SERCA PfATPase6 gene and artemisinin efficacy, and pointed it out as a potential molecular marker for resistance. The goal of this work was to describe the baseline polymorphism of PfATPase6 gene in Niger, at a time when the national implementation of the ACT policy had just begun.

Materials And Methods: The DNA polymorphism of the PfATPase6 gene of 87 P. falciparum samples from Niger was analysed by sequencing. The links between the mutation occurrence and environment and human host factors were tested by bivariate analysis.

Results: The P. falciparum PfATPase6 gene presented polymorphisms at codons 537, 561, 569, 630, 639, 716 levels. All the mutations found were rare, except the PfATPaseN569K found in 17.2% of samples. No associated factor has been observed.

Conclusion: The P. falciparum PfATPase gene is polymorphic at the 569 codon. As ACT is getting more and more used, the PfATPase6 gene polymorphism needs to be monitored in association with phenotypic - in vivo and/or in vitro - drug efficacy tests.

Citing Articles

Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria.

Nguetse C, Adegnika A, Agbenyega T, Ogutu B, Krishna S, Kremsner P Malar J. 2017; 16(1):217.

PMID: 28535801 PMC: 5442681. DOI: 10.1186/s12936-017-1868-y.

Limited artemisinin resistance-associated polymorphisms in Plasmodium falciparum K13-propeller and PfATPase6 gene isolated from Bioko Island, Equatorial Guinea.

Li J, Chen J, Xie D, Eyi U, Matesa R, Obono M Int J Parasitol Drugs Drug Resist. 2016; 6(1):54-59.

PMID: 27054064 PMC: 4805774. DOI: 10.1016/j.ijpddr.2015.11.002.

Genetic diversity and lack of artemisinin selection signature on the Plasmodium falciparum ATP6 in the Greater Mekong Subregion.

Miao M, Wang Z, Yang Z, Yuan L, Parker D, Putaporntip C PLoS One. 2013; 8(3):e59192.

PMID: 23555629 PMC: 3608609. DOI: 10.1371/journal.pone.0059192.

Characterization of the Plasmodium falciparum sarcoplasmic/endoplasmic reticulum Ca2+-ATPase gene in samples from Equatorial Guinea before implementation of artemisinin-based combination therapy.

Fernandez-Martinez A, Mula P, Cravo P, Charle P, Amor A, Ncogo P Am J Trop Med Hyg. 2012; 88(1):43-47.

PMID: 23185077 PMC: 3541744. DOI: 10.4269/ajtmh.2012.12-0364.

In vitro antimalarial susceptibility and molecular markers of drug resistance in Franceville, Gabon.

Zatra R, Lekana-Douki J, Lekoulou F, Bisvigou U, Ngoungou E, Ndouo F BMC Infect Dis. 2012; 12:307.

PMID: 23153201 PMC: 3534593. DOI: 10.1186/1471-2334-12-307.

References

Afonso A, Hunt P, Cheesman S, Alves A, Cunha C, do Rosario V . Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother. 2006; 50(2):480-9. PMC: 1366921. DOI: 10.1128/AAC.50.2.480-489.2006. View

Menegon M, Sannella A, Majori G, Severini C . Detection of novel point mutations in the Plasmodium falciparum ATPase6 candidate gene for resistance to artemisinins. Parasitol Int. 2008; 57(2):233-5. DOI: 10.1016/j.parint.2007.12.004. View

Ibrahim M, Gay-Andrieu F, Adehossi E, Lacroix V, Randrianarivelojosia M, Duchemin J . Field-based evidence for the linkage of pfcrt and pfdhfr drug-resistant malaria genotypes and clinical profiles of severe malaria in Niger. Microbes Infect. 2007; 9(5):599-604. DOI: 10.1016/j.micinf.2007.02.003. View

Ibrahim M, Hassane H, Konate L, Adamou S, Ousmane I, Adehossi E . [Plasmodium falciparum chloroquine and pyrimethamine resistance monitoring network with molecular tools in the Niger River valley, Republic of Niger]. Bull Soc Pathol Exot. 2008; 101(1):47-9. View

Cojean S, Hubert V, Le Bras J, Durand R . Resistance to dihydroartemisinin. Emerg Infect Dis. 2007; 12(11):1798-9. PMC: 3372362. DOI: 10.3201/eid1211.060903. View

Dugelay F, Adehossi E, Adamou S, Ousmane I, Parzy D, Delmont J . Efficacy of chloroquine in the treatment of uncomplicated, Plasmodium falciparum malaria in Niamey, Niger, in 2001. Ann Trop Med Parasitol. 2003; 97(1):83-6. DOI: 10.1179/00349803125002760. View

Crameri A, Marfurt J, Mugittu K, Maire N, Regos A, Coppee J . Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J Clin Microbiol. 2007; 45(11):3685-91. PMC: 2168483. DOI: 10.1128/JCM.01178-07. View

Jung M, Kim H, Nam K, No K . Three-dimensional structure of Plasmodium falciparum Ca2+ -ATPase(PfATP6) and docking of artemisinin derivatives to PfATP6. Bioorg Med Chem Lett. 2005; 15(12):2994-7. DOI: 10.1016/j.bmcl.2005.04.041. View

Mugittu K, Genton B, Mshinda H, Beck H . Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. Malar J. 2006; 5:126. PMC: 1764422. DOI: 10.1186/1475-2875-5-126. View

10.

Kimura M, Tanabe K, Krishna S, Tsuboi T, Saito-Ito A, Otani S . Gametocyte-dominant expression of a novel P-type ATPase in Plasmodium yoelii. Mol Biochem Parasitol. 1999; 104(2):331-6. DOI: 10.1016/s0166-6851(99)00153-x. View

11.

Dahlstrom S, Veiga M, Ferreira P, Martensson A, Kaneko A, Andersson B . Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6). Infect Genet Evol. 2008; 8(3):340-5. DOI: 10.1016/j.meegid.2008.02.002. View

12.

Parola P, Ali I, Djermakoye F, Crassard N, Bendavid C, Faugere B . [Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)]. Bull Soc Pathol Exot. 2000; 92(5):317-9. View

13.

Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B . Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005; 366(9501):1960-3. DOI: 10.1016/S0140-6736(05)67787-2. View

14.

Dhitavat J, Dode L, Leslie N, Sakuntabhai A, Lorette G, Hovnanian A . Mutations in the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase isoform cause Darier's disease. J Invest Dermatol. 2003; 121(3):486-9. DOI: 10.1046/j.1523-1747.2003.12410.x. View

15.

Eckstein-Ludwig U, Webb R, Van Goethem I, East J, Lee A, Kimura M . Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003; 424(6951):957-61. DOI: 10.1038/nature01813. View

16.

Zhang G, Guan Y, Zheng B, Wu S, Tang L . No PfATPase6 S769N mutation found in Plasmodium falciparum isolates from China. Malar J. 2008; 7:122. PMC: 2467427. DOI: 10.1186/1475-2875-7-122. View

17.

Ferreira I, Lopes D, Martinelli A, Ferreira C, do Rosario V, Cravo P . In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from São Tomé and Príncipe. Trop Med Int Health. 2007; 12(3):353-62. DOI: 10.1111/j.1365-3156.2006.01789.x. View